Skip to Main Content

Chandler, Kevin Brown, PhD

Title: Assistant Professor

Office: AHC5-256

Phone: 305-348-9136

Email: kchandle@fiu.edu

Department(s): Translational Medicine

Kevin Chandler is a researcher in the Translational Glycobiology Institute at Florida International University (TGIF). He is a Harvard ProTG K12 Program Scholar under the mentorship of TGIF founders
Dr. Robert Sackstein, Dean of the College of Medicine, and Charles Dimitroff, Executive Associate Dean for Research.

Chandler’s research interests include understanding how aberrant protein glycosylation contributes to the pathogenesis of oral cancer, and the application of this knowledge to improve cancer diagnosis and treatment. His background is in biochemistry and analytical chemistry with a focus on mass spectrometry-based analyses of glycoproteins as applied to tumor angiogenesis and tumor biology.

The goal of his current research is to understand how N-glycosylation regulates (1) epidermal growth factor receptor (EGFR) signaling in oral squamous cell carcinoma (OSCC), and (2) vascular endothelial growth factor receptor (VEGFR2) in colorectal cancer. His research has recently demonstrated a role for β-catenin and CREB-binding protein (CBP) in altering fucosyltransferase activity in oral cancer.

Education:

Ph.D. in Biochemistry and Molecular Biology, Georgetown University, Washington, D.C.
B.S. in Biochemistry and Molecular Biophysics, University of Arizona, Tucson, Arizona

Selected Publications:

 View the full list of Kevin Chandler's publications.

  1. Chandler KB, Alamoud KA, Stahl VL, Nguyen BC, Kartha VK, Bais MV, Nomoto K, Owa T, Monti S, Kukuruzinska MA, Costello CE. β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. Mol Omics. 2020 Jun 1;16(3):195-209. doi: 10.1039/d0mo00009d. Epub 2020 Mar 23. PMID: 32203567; PMCID: PMC7299767.
  2. Chandler KB, Leon DR, Kuang J, Meyer RD, Rahimi N, Costello CE. N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2). J Biol Chem. 2019 Aug 30;294(35):13117-13130. doi: 10.1074/jbc.RA119.008643. Epub 2019 Jul 15. PMID: 31308178; PMCID: PMC6721943.
  3. Chandler KB, Costello CE, Rahimi N. Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. Cells. 2019 Jun 5;8(6). doi: 10.3390/cells8060544. Review. PMID: 31195728; PMCID: PMC6627046.
  4. Chandler KB, Mehta N, Leon DR, Suscovich TJ, Alter G, Costello CE. Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles. Mol Cell Proteomics. 2019 Apr;18(4):686-703. doi: 10.1074/mcp.RA118.001185. Epub 2019 Jan 18. PMID: 30659065; PMCID: PMC6442369.
  5. Chandler KB, Leon DR, Meyer RD, Rahimi N, Costello CE. Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2. J Proteome Res. 2017 Feb 3;16(2):677-688. doi: 10.1021/acs.jproteome.6b00738. Epub 2016 Dec 29. PMID: 27966990; PMCID: PMC5291786.